ArticleMedicine2026
Associations between urinary iodine concentration and metabolically dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: Evidence from the NHANES database 2001-2020.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Given the potential significance of iodine in the development of metabolic dysfunction-associated steatotic liver disease (MASLD), this study aims to investigate the associations between urine iodine concentration (UIC), MASLD, and advanced liver fibrosis. Using data from the National Health and Nutrition Examination Survey. Logistic analysis generated odds ratios (OR) and 95% confidence intervals (CI) to assess the impact of iodine status. Restricted cubic spline (RCS) functions were applied to detect nonlinear relationships between UIC and MASLD/advanced liver fibrosis. Receiver operating characteristic curves evaluated UIC's predictive capacity. The robustness of the findings was assessed via sensitivity analyses, and differences across populations were examined through subgroup analyses. Following comprehensive adjustments, lower UIC individuals exhibited lower odds for MASLD (OR 0.77; 95% CI: 0.61-0.99) and advanced liver fibrosis (OR 0.58; 95% CI: 0.38-0.89) in comparison to those with normal UIC. Stratifying by UIC quartiles, the third quartiles (OR 1.56; 95% CI: 1.18-2.07) and fourth quartiles (OR 1.58; 95% CI: 1.23-2.00) were associated with increased MASLD risk, a finding further confirmed in sensitivity analyses. RCS analysis revealed a nonlinear relationship between UIC concentration and the risk of MASLD. Subgroup analyses did not reveal any heterogeneity in this study. A low urinary iodine concentration is associated with a diminished risk of MASLD and advanced liver fibrosis, whereas elevated iodine levels were significantly linked to an increased MASLD risk. Longitudinal and experimental studies are necessary to elucidate causality and guide clinical recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.